FourThought Financial Partners LLC Sells 152 Shares of Edwards Lifesciences Co. (NYSE:EW)

FourThought Financial Partners LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 4.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,125 shares of the medical research company’s stock after selling 152 shares during the period. FourThought Financial Partners LLC’s holdings in Edwards Lifesciences were worth $238,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of EW. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $34,000. Operose Advisors LLC raised its stake in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after buying an additional 452 shares during the period. SRS Capital Advisors Inc. raised its stake in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after buying an additional 474 shares during the period. NBC Securities Inc. acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $52,000. Finally, ORG Partners LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $66,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares in the company, valued at approximately $388,801.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 237,749 shares of company stock worth $20,920,934. 1.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EW shares. Wells Fargo & Company raised their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Piper Sandler lifted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Oppenheimer lifted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Stock Down 0.1 %

Shares of EW traded down $0.05 during trading hours on Monday, reaching $85.20. 633,398 shares of the stock traded hands, compared to its average volume of 3,736,108. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The stock has a fifty day simple moving average of $90.08 and a 200 day simple moving average of $79.46. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company has a market cap of $51.34 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.